This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​India Competition Commission approves divestment in Sun Pharma, Ranbaxy deal

( March 24, 2015, 02:43 GMT | Official Statement) -- MLex Summary: The Competition Commission of India, after conducting an assessment, approved the divestment of products under seven brands of Sun Pharmaceutical Industries and Ranbaxy Laboratories to Emcure Pharmaceuticals in connection with the proposed merger of Sun Pharma and Ranbaxy. The CCI said Emcure is a suitable purchaser of the divested products and the acquisition won’t cause any appreciable adverse effect on competition in the relevant market. The merger was conditionally approved by the CCI last December.The full statement is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections